GlassScriptPhysician profile
Damanpreet Ubhi
NPI 1346410560
$2,130.53
in general payments reported to CMS, 2019-2025
27 companies · $596 in 2025
The $596 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $447 · 2021: $211 · 2022: $163 · 2023: $91.25 · 2024: $398 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,085.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Musculoskeletal Transplant Foundation INC. | $633.35 | 2020-2024 | |
| Organogenesis INC. | $258.39 | 2021-2025 | Nushield |
| Smith+Nephew, INC. | $218.78 | 2019-2024 | Pico 7, Collagenase Santyl |
| Abbvie INC. | $121.74 | 2024-2025 | |
| Gilead Sciences, INC. | $119.95 | 2019-2025 | Biktarvy |
| Urgo Medical North America, LLC | $94.51 | 2024-2025 | Urgoclean Ag, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Merck Sharp & Dohme LLC | $74.86 | 2025 | Zerbaxa, Pifeltro |
| Insmed, INC. | $71.77 | 2025 | Arikayce, Brinsupri |
| Aimmune Therapeutics, INC. | $53.65 | 2025 | Vowst |
| Solventum Corporation | $45.31 | 2024-2025 | Activ.A.C., Promogran Prisma, V.A.C. Dermatac |
| Hill-Rom Company, INC | $44.72 | 2019 | |
| Kci USA, INC. | $43.37 | 2020-2021 | |
| Grifols USA, LLC | $41.54 | 2025 | Xembify |
| Abbott Laboratories | $36.91 | 2023 | Supera, Jeti |
| Shionogi INC | $34.34 | 2025 | Fetroja |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $27.00 | 2019 | |
| Rgh Enterprises LLC | $26.41 | 2024 | |
| Misonix INC | $25.49 | 2021 | |
| Molnlycke Health Care US, LLC | $23.90 | 2025 | Mepilex Lite, Mepilex Ag, Mepilex Border Flex |
| Melinta Therapeutics, LLC | $20.12 | 2025 | Rezzayo, Orbactiv, Kimyrsa |
| Viiv Healthcare Company | $18.69 | 2025 | Cabenuva |
| Osiris Therapeutics INC. | $17.95 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.48 | 2025 | Nuzyra |
| Pfizer INC. | $16.61 | 2024 | |
| Tactile Systems Technology INC | $15.21 | 2020 | |
| Hartmann USA, INC. | $14.76 | 2025 | Zetuvit Plus 10x10 P10 |
| Convatec INC. | $13.72 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damanpreet Ubhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.